Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Rik de Greef"'
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Oncology drug discovery and development has always been an area facing many challenges. Phase 1 oncology studies are typically small, open-label, sequential studies enrolling a small sample of adult patients (i.e., 3-6 patients/cohort) in dose escala
Externí odkaz:
https://doaj.org/article/a33f9e0c7f654f328f3461dab95da55b
Autor:
Bhargava Kandala, Nele Plock, Akshita Chawla, Anna Largajolli, Seth Robey, Kenny Watson, Raj Thatavarti, Sheri A. Dubey, S.Y. Amy Cheung, Rik de Greef, Julie Stone, Jeffrey R. Sachs
Publikováno v:
EBioMedicine, Vol 84, Iss , Pp 104264- (2022)
Summary: Background: The COVID-19 pandemic has increased the need for innovative quantitative decision tools to support rapid development of safe and efficacious vaccines against SARS-CoV-2. To meet that need, we developed and applied a model-based m
Externí odkaz:
https://doaj.org/article/de1aa37726f44b35900d070763f50f39
Autor:
Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis, Julie A. Stone
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies;
Externí odkaz:
https://doaj.org/article/182d21e5687543179e830a09e90b9fdf
Autor:
Tien-Yi, Lee, Philippe Bernard, Pierrillas, Yu-Wei, Lin, Rik, de Greef, Anthe Suzanne, Zandvliet, Emilie, Schindler, Elizabeth, Migoya
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:124-134
Relugolix, the first orally active, nonpeptide gonadotropin-releasing hormone receptor antagonist, is approved in the United States and the European Union for the treatment of adult patients with advanced prostate cancer. The recommended dosing regim
Autor:
Jamie N. Connarn, Han Witjes, Marielle van Zutphen‐van Geffen, Rik de Greef, Timothy B. Campbell, Kristen Hege, Simon Zhou, Manisha Lamba
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology.
Autor:
David C. Turner, Russ Wada, Helen Zhou, Xiaowei Wang, Rik de Greef, Chandni Valiathan, Lindsey Zhang, Nancy Zhang, Mita Kuchimanchi, Tai‐Tsang Chen, Marc Ballas, Sandra A. G. Visser
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology.
Autor:
Takashi Iwasa, Camila de Almeida, Floris Fauchet, Gregory A. Winchell, Rik de Greef, Chihiro Hasegawa, Hiroyuki Yoshitsugu, Rebecca Ellen Wrishko
Publikováno v:
Journal of clinical pharmacologyReferences.
Posaconazole is a globally approved broad-spectrum triazole antifungal compound. In Japanese patients, posaconazole has identical dosing regimens as those approved globally for both tablet and intravenous formulations. This article aims to describe a
Autor:
Brendan Carvalho, Qian Long, Lihong Du, Ahmet Metin Gülmezoglu, Pisake Lumbiganon, Han Witjes, Vitaya Titapant, Olufemi T Oladapo, Rik de Greef, Lelia Duley, Kiattisak Kongwattanakul, Kathleen F. Brookfield, Larissa Wenning, Ussanee Sangkomkamhang
Publikováno v:
Journal of Clinical Pharmacology
Magnesium sulfate is the anticonvulsant of choice for eclampsia prophylaxis and treatment; however, the recommended dosing regimens are costly and cumbersome and can be administered only by skilled health professionals. The objectives of this study w
Autor:
Anna Largajolli, Malidi Ahamadi, Akshita Chawla, Thomas Kerbusch, Ferdous Gheyas, Rik de Greef, Paul M. Diderichsen, Han Witjes, Casey B. Davis
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 46:273-285
Stepwise covariate modeling (SCM) is a widely used tool in pharmacometric analyses to identify covariates that explain between-subject variability (BSV) in exposure and exposure–response relationships. However, this approach has several potential w
Autor:
Anna Largajolli, Nele Plock, Bhargava Kandala, Akshita Chawla, Seth H Robey, Kenny Watson, Raj Thatavarti, Sheri Dubey, S Y Amy Cheung, Rik de Greef, Jeffrey R Sachs
Publikováno v:
Open Forum Infectious Diseases
Background Several COVID-19 vaccines have been authorized, and the need for rapid, further modification is anticipated. This work uses a Model-Based Meta-Analysis (MBMA) to relate, across species, immunogenicity to peak viral load (VL) after challeng